By Aphios Corp.
Phospholipid Nanosomes for the intravenous or topical administration of proteins, genes, siRNA, hydrophilic molecules and hydrophobic anticancer drugs. Our enabling nanotechnologies for the enhanced delivery of therapeutics ranging from large macromolecules to potent but water-insoluble small molecules. The key advantage and differentiator of our drug delivery platforms is that they do not utilize organic solvents which could denature the target molecule being encapsulated and/or leave residual toxic organic solvents in the nanoparticles. Additionally, the technologies are environment-friendly, scalable and can be operated in a continuous flow mode. We are utilizing these nanotechnology drug delivery platforms for the development of several enhanced therapeutic products. We will partner with pharmaceutical and biotechnology companies to improve the delivery of novel drug candidates or to reformulate existing drugs.
